ArticleBMC cancer2015
Prognostic significance of ST3GAL-1 expression in patients with clear cell renal cell carcinoma.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Glycosylation in kidney diseases.Precision clinical medicine · 2025Review
- Integrated in vivo functional screens and multiomics analyses identify α-2,3-sialylation as essential for melanoma maintenance.Science advances · 2025Article
- Glycosylation in Cancer.Handbook of experimental pharmacology · 2025Review
- Sialylation-immune-related lncRNAFrontiers in immunology · 2025Article
- Metabolic Signaling in Cancer Metastasis.Cancer discovery · 2024Review
- Role of a Disease-associated ST3Gal-4 in Non-small Cell Lung Cancer.Cell biochemistry and biophysics · 2022Article
- Review
- Review
- Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?Cancers · 2021Review
- The expression and functional analysis of the sialyl-T antigen in prostate cancer.Glycoconjugate journal · 2020Article
- Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey.Clinical chemistry and laboratory medicine · 2019Review
- DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.BMC cancer · 2019Article
- Long noncoding RNA HOTAIR promotes renal cell carcinoma malignancy through alpha-2, 8-sialyltransferase 4 by sponging microRNA-124.Cell proliferation · 2018Article
- Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma.Oncotarget · 2018Article
- IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma.Oncotarget · 2017Article
- Article
- Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAberrant sialylated carbohydrate synthesis is frequently noted in various cancers. Sialyltransferase ST3GAL-1, which adds a sialic acid in an α-2,3 linkage to Gal β1,3 GalNAc, preforms an important role in modulating cellular behaviors. However, little is known about prognostic significance of ST3GAL-1 in clear cell renal cell carcinoma (ccRCC). In this study, we aimed to investigate the prognostic significance of sialyltransferase ST3GAL-1 and its correlation with clinical outcomes in patients with ccRCC.
methodsA total of 286 patients who underwent nephrectomy between 2005 and 2007 in a single academic center were recruited. Immunohistochemical staining was performed on tissue microarrays to assess the expression level. Kaplan-Meier method and Cox proportional hazard model were applied to assess the prognostic value of ST3GAL-1. Nomograms were generated as prediction model for overall survival and disease free survival at 5 and 8 years after nephrectomy.
resultsThe present results show high expression of ST3GAL-1 is associated with reduced overall survival (p = 0.013) and disease free survival (p = 0.004). In multivariate cox analyses, ST3GAL-1 was defined as an independent prognostic factor for overall survival (p = 0.006) and disease free survival (p = 0.001). After incorporation into the University of California Integrated Staging System (UISS) intermediate/high risk group for non-metastatic ccRCC, ST3GAL-1 could further distinguish patient with dismal prognosis (p = 0.015 and 0.002 for OS and DFS respectively). The nomograms revealed better predictive accuracy in predicting 5- and 8- year overall survival and disease free survival than the TNM stage alone.
conclusionsST3GAL-1 is an independent adverse prognostic factor for recurrence and survival of patients with ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.